Index of reports
> Cases with Maternal Exposure During Pregnancy (1)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Bravelle (Urofollitropin) where reactions include maternal exposure during pregnancy. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Bravelle side effects in female
Reported by a consumer/non-health professional from United States on 2011-10-19
Patient: female, weighing 79.4 kg (174.6 pounds)
Reactions: Maternal Exposure During Pregnancy, Abortion Spontaneous
Drug(s) suspected as cause:
Bravelle
Dosage: (150 -0225 iu everyday (qd))
Indication: in Vitro Fertilisation
Start date: 2009-11-01
End date: 2009-11-23
Menotropins
Indication: in Vitro Fertilisation
Start date: 2009-11-01
End date: 2009-11-23
Other drugs received by patient: Prenatal Vitamins / 01549301 /; Progesterone
|